Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 18, 2025 17:56 ET | Source: Robbins LLP

Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders of the Pending Lead Plaintiff Deadline in the Securities Class Action Against SRPT

Robbins LLP is Investigating Allegations that Sarepta Therapeutics, Inc. (SRPT) Mislead Investors Regarding the Safety its ELEVIDYS Drug
August 14, 2025 19:25 ET | Source: Robbins LLP

Robbins LLP Urges NVO Stockholders with Large Losses to Contact the Firm for Information about Leading the Class Action Against Novo Nordisk A/S

Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled the Market About its 2025 Revenue and Profit Growth Potential
July 25, 2025 15:22 ET | Source: Robbins LLP

BHVN Class Action Alert: Robbins LLP Reminds Biohaven Ltd. Stockholders of the Lead Plaintiff Deadline in the Class Action Against BHVN

Robbins LLP is Investigating Allegations that Biohaven Ltd. (BHVN) Misled Investors Regarding the Viability of its Candidate
July 21, 2025 17:36 ET | Source: Robbins LLP

BHVN Class Action Alert: Robbins LLP Reminds Biohaven Ltd. Stockholders of the Lead Plaintiff Deadline in the Class Action Against BHVN

Robbins LLP is Investigating Allegations that Biohaven Ltd. (BHVN) Misled Investors Regarding the Viability of its Candidates
July 03, 2025 19:41 ET | Source: Robbins LLP

Robbins LLP Urges HIMS Stockholders with Large Losses to Contact the Firm for Information About the Class Action Pending Against Hims & Hers Health, Inc.

Robbins LLP is Investigating Allegations that Hims & Hers Health, Inc. (HIMS) Deceptively Promoted and Sold Illegitimate Versions of Wegovy®
June 30, 2025 20:34 ET | Source: Robbins LLP

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information

Robbins LLP is Investigating Allegations that UroGen Pharma Ltd. (URGN) Failed to Conduct a Proper Trial for its Lead Drug Candidate
June 30, 2025 20:16 ET | Source: Robbins LLP

OGN Stock News: Robbins LLP Reminds Organon & Co. Investors of the Pending Lead Plaintiff Deadline in the OGN Class Action – Contact Robbins LLP Before July 22 for Information

Robbins LLP is Investigating Allegations that Organon & Co. (ORG) Misled Investors Regarding its Debt Reduction Strategy
June 27, 2025 19:14 ET | Source: Robbins LLP

PEPG Stockholders With Large Losses are Encouraged to Contact Robbins LLP for Information About the Securities Class Action Lawsuit Against PepGen Inc.

Robbins LLP is Investigating Allegations that PepGen Inc. (PEPG) Misled Investors Regarding the Viability of its Drug Candidate
June 27, 2025 19:13 ET | Source: Robbins LLP

RCKT Investors With Large Losses are Encouraged to Contact Robbins LLP for Information About the Securities Class Action Filed Against Rocket Pharmaceuticals, Inc.

Robbins LLP is Investigating Allegations that Rocket Pharmaceuticals, Inc. (RCKT) Misled Investors Regarding the Viability and Efficacy of RP-A501
June 13, 2025 20:28 ET | Source: Robbins LLP

RCKT Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Rocket Pharmaceuticals, Inc.

Robbins LLP is Investigating Allegations that Rocket Pharmaceuticals, Inc. (RCKT) Misled Investors Regarding the Viability and Efficacy of RP-A501